Previous 10 | Next 10 |
Monday wasn't a good day on Wall Street, as major benchmarks started the final month of 2019 with across-the-board declines. The White House reignited trade disputes by taking away a previous exemption to steel tariffs for imports from Brazil and Argentina, and market watchers wondered what migh...
Gainers: Kodiak Sciences (NASDAQ: KOD ) +70% . More news on: Kodiak Sciences Inc., ASLAN Pharmaceuticals Limited, Cortexyme, Inc., Stocks on the move, Read more ...
Aqua Metals (NASDAQ: AQMS ) -41% after fire broke out at the plant. More news on: Aqua Metals, Inc., Lexicon Pharmaceuticals, Inc., Paringa Resources Limited, Stocks on the move, Read more ...
The FDA has denied Lexicon Pharmaceuticals' (NASDAQ: LXRX ) appeal of the CRL it received in March related to its marketing application for type 1 diabetes med sotagliflozin. Undeterred, it now plans to appeal the decision to the Center for Drug Evaluation and Research (CDER). More new...
THE WOODLANDS, Texas, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has reiterated the FDA's prior position and denied Lexicon's appeal of the Complete Response ...
Lexicon Pharmaceuticals ( LXRX ) is now in a “hurry up and wait” limbo, as the company waits for clarity on its dispute resolution petition with the FDA regarding Zynquista in Type 1 diabetes and as investors wait for more information and clarity on the clinical profile of Zynq...
It's been a rough year for Lexicon Pharmaceuticals (NASDAQ: LXRX) . In fact, it's been a rough five years for the pharmaceutical stock, which has lost 49% in that span. The business has struggled to generate much momentum for its lone drug product, Xermelo, a treatment for carcinoid syndrome...
Gainers: LXRX +2.5% . CLNY +2.3% . VMW +1.7% . UPLD +1.5% . OXLC +1.5% . More news on: Lexicon Pharmaceuticals, Inc., Colony Capital, Inc., VMware, Inc., Stocks on the move, Read more ...
Lexicon Pharmaceuticals, Inc (LXRX) Q3 2019 Earnings Conference Call November 7, 2019 08:00 ET Company Participants Lonnel Coats - President and Chief Executive Officer Alex Santini - Executive Vice President and Chief Commercial Officer Dr. Pablo Lapuerta - Executive Vice Presid...
Image source: The Motley Fool. Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) Q3 2019 Earnings Call Nov 7, 2019 , 8:00 a.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...